Skip to main content
. 2023 Feb 16;38:100888. doi: 10.1016/j.neo.2023.100888

Fig. 4.

Fig 4

Comparing the molecular features of NSCLC patients with L858R or 19-Del mutations. a. Somatic mutations showed differential distribution in patients with L858R and 19-Del mutations. b. Mutations in the TGFβ signaling pathway were enriched in patients with 19-Del. c. No significant difference was observed in TMB between the two cohorts. d. Mutational signatures attributed by L858R and 19-Del mutations. e. Kaplan-Meier estimates of PFS in L858R-positive or 19-Del-positive NSCLC patients with or without ARID2 mutations.